Similarly, we defined a neo-peptide as a neo-epitope based on a single positive assay; however, immunogenicity is context-dependent and varies across cancer types and patients, likely due to differences in expression levels, MHC presentation machinery, immune infiltration, or T cell diversity. The gene discussed is HLA-C; the disease is cancer.